Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill Magnificent Seven ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Roundhill Magnificent Seven ETF trades at $73.54 (market cap $5.78B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 424.4× Citius Pharmaceuticals Inc's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| CTXR | MAGS | |
|---|---|---|
Market Cap | $13.62M | $5.78B |
Volume | 132,438 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $73.90 |
52-Week Low | $0.48 | $55.39 |
Typical Hold Time | 16 Days | 36 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the S&P 500 in 2026 with only 2% YTD gains. Recent news highlights AI-driven momentum from holdings like Meta and NVIDIA, but also notes the Magnificent Seven theme showing signs of fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but concentration risk and valuation concerns persist. Key opportunities include pure-play exposure to AI growth engines, while risks involve market rotation away from mega-caps and aggressive capital expenditure cycles impacting shareholder returns. Technical support sits at $73 with resistance at $74-75.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
